NeoDynamics signs manufacturing agreement for NeoNavia
NeoDynamics has signed an agreement with a world class contract manufacturer to prepare market introduction of the company’s new breast cancer biopsy system NeoNavia® and scale up production of the new biopsy probe models.
NeoDynamics AB (publ) today announce that it has signed an agreement with a contract manufacturer to scale up production and prepare introduction of the new NeoNavia® biopsy probe models to the market.The signing of the manufacturing service agreement is an important milestone for NeoDynamics and clearly demonstrates the shift in focus towards volume manufacturing readiness.
The contract manufacturer is a well-established FDA listed Asian manufacturing company. The volume manufacturer is already an approved supplier to NeoDynamics and a valuable partner to the development team.
“With this new agreement in place, we are well prepared and ready for scaling our supply chain and continue our efforts of bringing the new NeoNavia biopsy system to market. Working with leading suppliers is both rewarding and fun and I am really looking forward to taking this partnership to a new level and prepare the ground for a successful introduction”, says Magnus Olsen, Chief Development & Operations Officer, NeoDynamics.
For further information about NeoDynamics, please contact:
Anna Eriksrud, CEO NeoDynamics AB (publ), telephone: +46 8 522 79 667, e-mail: firstname.lastname@example.org, or
Jörgen Vrenning, CFO/IR NeoDynamics AB (publ), Telephone: +46 708 519 648, email: email@example.com
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has an innovative biopsy system, NeoNavia® , in late stage development. The precision biopsy system is built on a patented micro-pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia® is evaluated at leading clinics in UK, Germany and Sweden. A commercial launch is expected in 2020.
NeoNavia is the brand name for the entire biopsy system intended to be used under ultrasound guidance. NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the micro-pulses enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
About the micro-pulse technology
The patented micro-pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type. The pneumatic driver that generates micro-pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.